NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2023 OBIO Investment Summit.
The OBIO Investment Summit will be hosted at the World Trade Centre Toronto on February...
Montreal / July 4, 2022
NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation Awards Gala has become a must-attend event in the Quebec ecosystem.
The 32nd ADRIQ Innovation Awards Gala will take place on Thursday, November...
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2022 OBIO Investment Summit.
The OBIO Investment Summit will be hosted virtually February 9-11, 2022, and NexPlasmaGen was selected...
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022
NexPlasmaGen will pitch its business opportunity to investors!
Montreal/December 24 – NexPlasmaGen, today announced that it is presenting at Seed Showcase, part of the Biotech Showcase™ 2022 conference. This year, in addition to seeing NexPlasmaGen scheduled presentation delivered onsite via...
NexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal was successfully completed. The first stage of the program demonstrated that NexPlasmaGen's Convertible Plasma Jet (CPJ) was able to destroy breast cancer...
NexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program and the federal MITACS and CNRC-IRAP programs to accelerate the development of its patented cold plasma technology, the APGDT, as an adjuvant...